HAMLET B — Hamlet BioPharma AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK603.95m
- SEK572.37m
Annual balance sheet for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 13.2 | 7.47 | 39.6 | 18.4 | 23.1 |
| Net Total Receivables | 0.754 | 0.496 | 0.847 | 0.49 | 3.73 |
| Prepaid Expenses | |||||
| Total Current Assets | 14.5 | 12.7 | 41.7 | 19 | 27.3 |
| Net Property, Plant And Equipment | 0.045 | 0.009 | 0 | 0 | 0.574 |
| Net Intangible Assets | |||||
| Total Assets | 14.6 | 12.7 | 41.7 | 28.5 | 68.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.08 | 9.99 | 3.72 | 2.55 | 4.11 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 4.08 | 9.99 | 3.72 | 7.55 | 4.11 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 10.5 | 2.75 | 38 | 20.9 | 64.5 |
| Total Liabilities & Shareholders' Equity | 14.6 | 12.7 | 41.7 | 28.5 | 68.6 |
| Total Common Shares Outstanding |